NUVAIRA Revenue and Competitors

Location

$188.9M

Total Funding

Estimated Revenue & Valuation

  • NUVAIRA's estimated annual revenue is currently $7M per year.(i)
  • NUVAIRA's estimated revenue per employee is $125,500
  • NUVAIRA's total funding is $188.9M.

Employee Data

  • NUVAIRA has 56 Employees.(i)
  • NUVAIRA grew their employee count by -21% last year.

NUVAIRA's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Science, Clinical, and R&DReveal Email/Phone
3
SVP Global Market DevelopmentReveal Email/Phone
4
ControllerReveal Email/Phone
5
Human Resources DirectorReveal Email/Phone
6
Director, Supply Chain and ManufacturingReveal Email/Phone
7
Director Market DevelopmentReveal Email/Phone
8
Director QualityReveal Email/Phone
9
Director Research and DevelopmentReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$30.6M1224%N/AN/A
#2
$18.6M7435%N/AN/A
#3
$75.6M30120%N/AN/A
#4
$12M484%N/AN/A
#5
$2.8M1110%N/AN/A
#6
$3M120%N/AN/A
#7
$24.6M985%N/AN/A
#8
$11.5M4621%N/AN/A
#9
$7.3M294%N/AN/A
#10
$13.8M55-10%N/AN/A
Add Company

What Is NUVAIRA?

Nuvaira, Inc., is a privately held medical device company that develops minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases. Specifically, the company is developing a novel, catheter-based system to address chronic obstructive pulmonary disease, or COPD, by treating the overactive airway nerves in a procedure call Targeted Lung Denervation* (TLD). *Targeted Lung Denervation (TLD) is currently under clinical investigation for chronic obstructive pulmonary disease and is not yet commercially available. Nuvaira and dNerva are trademarks of Nuvaira, Inc.

keywords:N/A

$188.9M

Total Funding

56

Number of Employees

$7M

Revenue (est)

-21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NUVAIRA News

2022-02-22 - 200th Treatment Milestone for AIRFLOW-3 COPD Trial

300 Patients Treated Worldwide with dNerva® Targeted Lung Denervation therapy. MINNEAPOLIS, Jan. 25, 2022 /PRNewswire/ -- Nuvaira,...

2021-08-11 - Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone USA - English España - español France - Français Deutschland - Deutsch

MINNEAPOLIS, Aug. 11, 2021 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that 100 patients have been randomized in the FDA pivotal AIRFLOW-3 Clinical Trial. This COPD trial is evaluating the safety and effectiveness of th ...

2020-11-23 - Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation USA - English France - Français Deutschland - Deutsch España - español

MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today publication of two-year follow-up data from its randomized, sham-controlled, double-blinded trial (AIRFLOW-2) that confirms long-term safety and d ...

2019-02-13 - Minneapolis-Based Nuvaira Raises $79 Million To Fight Chronic Lung Diseases

Nuvaira, a Minneapolis, Minnesota-based developer of novel therapeutic medical devices for treating obstructive lung diseases, has raised $79 million in funding led by U.S. Venture Partners. Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation also jo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.6M56-12%N/A
#2
$6.8M56-25%$4.1M
#3
$12.7M56-10%N/A
#4
$7.1M5627%N/A
#5
$13.6M568%N/A